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Summarv Five patients with advanced colorectal and gastric carcinoma With peritoneal deposits were treated
by continuous weekdays intraperitoneal (i.p.) instillation of 5-fluorouracil (5-FU) 200 mg m-- day' in a novel
dialysate solution that ensures maximal exposure of peritoneal areas liable to bear tumours for 24 h. A
solution of icodextrin. a glucose polymer. in a 21 twin-bag delivery system allowed a single daily exchange and
demonstrated the feasibility of long-term continuous ambulatory treatment with up to 17.4 g of 5-FU.
delivered intraperitoneally. in this initial study. During the entire study. there were 235 fluid exchanges or 470
connections and disconnections and no bacterial peritonitis or exit site infection were observed. There was no
treatment-associated toxicity worse than WHO grade 2. Drug concentrations in both peritoneal and plasma
compartments followed a first-order model with similar half-life value of 1.3 h. 5-FU pharmacokinetic
parameters (half-life values, total body clearance. peritoneal clearance and pharmacological advantage of the
i.p. route) with this novel icodextrin carrier solution were similar to those obtained in other referenced
pharmacokinetic studies with other carrier solutions (dextrose dialysate and lactated Ringer's solutions). This
confirms that icodextrin solution is physiologically neutral. drug compatible and allows adequate dwell times
with constant fluid balance for long-term continuous intraperitoneal chemotherapy. The pharmacokinetic
parameters from this study will be used to design a loading dose infusion schedule in an attempt to maintain
steady-state i.p. 5-FU levels in a new multicentre phase I trial.
Intraperitoneal (i.p.) and intracavity administration of anti-
tumour drugs has been performed since the early days of
modern cancer chemotherapy. Intraperitoneal infusion of an
appropriate cytotoxic agent is still in many patients the most
efficient palliative therapy for malignant ascites arising from
carcinomatosis peritonei (Weisberg et al., 1955: Clarkson et
al.. 1964: Suhrland & Weisberger. 1965; Casper et al.. 1983).
The ability to deliver drugs into the abdominal cavity on a
regular or continuous basis has frequently been frustrated by
the non-availability of a safe delivery system. High complica-
tion rates due to catheter flow obstruction, infection and
abdominal pain or discomfort (Piccart et al., 1985) have
limited the use of this route of administration. Similarly,
available carrier solutions tend to be rapidly absorbed, thus
making peritoneal exposure to the drugs patchy and
erratic.
Up to 2 1 of fluid is required for adequate immersion of all
peritoneal areas liable to bear tumours (Wahl et al., 1989).
Thus. continuous. peritoneal coverage requires frequent
regular administration of large volumes of electrolyte solu-
tion. which may result in fluid overloading and or unaccept-
able excretion of massive urine volumes.
Continuous. ambulatory peritoneal dialysis (CAPD) has
revolutionised our knowledge. experience and ability to em-
ploy the peritoneal cavity for therapeutic purposes. and
anephric patients have now been maintained on CAPD for
up to 15 years (Bengmark. 1989). From these developments
have come proven. safe delivery systems which protect the
patient from peritonitis (Verger & Luzar, 1986; Rottembourg
et al.. 1987) and new carnrer solutions. based on the use of
glucose polymers as osmotic agents. which remain within the
peritoneal cavity for 24 h with minimal exchanges of fluid or
electrolytes (Mistry et al.. 1985. 1987).
Thus. the technologN and practical clinical experience of
peritoneal dialysis has now provided. for the first time. the
opportunity to meet the long sought after therapeutic
requirements for adequate. long-term continuous exposure of
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peritoneal tumour deposits to cytotoxic agents.
Previous studies (Speyer et al.. 1981: Speyer. 1985: Sugar-
baker et al.. 1985: Ekberg et al.. 1988: Goldberg et al.. 1988:
Sugarbaker. 1991: Hallenbeck et al.. 1992) have shown that
5-FU has single-agent activity in the treatment of the col-
orectal carcinomas confined to or recurrent in the peritoneal
cavity and has a large pharmacokinetic regional advantage
following i.p. instillation. i.e. the drug is cleared much more
rapidly from the systemic circulation than from the per-
toneal cavity.
Recently. it has been shown that prolongation of intra-
venous infusion (e.g. to 10 weeks) of 5-FU is associated with
an increased response rate in patients with advanced colorec-
tal carcinoma (Seifert. 1975: Lokich et al.. 1989: Leichman et
al.. 1993). The aim of the present study was to determine the
pharmacokinetics of 5-FU following intraperitoneal adminis-
tration in a novel dextrin carrier solution during a 24 h dwell
time and to assess the peritoneal fluid balance profile (in and
out i.p. fluid volumes). peritoneal cytology and associated
toxicitY.
Patients and methods
Patients and eligibility criteria
Five patients with a histologically documented intra-abdom-
inal malignancy (four colorectal and one gastric carcinoma)
were enrolled in this study. The patients' characteristics are
given in Table I.
The patients had normal haematological, renal and hepatic
indices and a WHO performance status of better than 2. The
protocol was approved by the institutional ethics committee
review board and all patients provided written, informed
consent.
Treatment plan
Four to 5 weeks prior to initiation of chemotherapy. all
patients had a Tenckhoff catheter peritoneal access system
surgically placed in theatre. Immediately following catheter
placement, several washout exchanges with icodextrin solu-
tions were performed to prevent clogging of the catheter and
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Tbe I Patient characteristics and i.p. chemotherapy treatment duration
Total number of
4ge Disease Previous dais on ip. Total 5-FL dose
Sex y-ears) Site ofprimari Peritoneal disease Ascites elsewhere treatment chemotherapy delivered ip. (g}
M 58 Caecum and At laparotomy No Liver metastases 5-FU folinic acid 19 (over 4 weeks) 6.624
liver widespread and PALA
peritoneal
nodules (positive
biopsy)
F 64 Sigmoid colon Laparotomx for No Liver metastases No 21 (over 5 weeks) 5.657
adherent to liver and
anterior pentoneal
abdominal metastases
wall
M 59 Sigmoid colon Retropen'toneal No No No 18 (over 4 weeks) 5.709
lymph nodes
M 48 Stomach Inoperable Yes Pancreas No 38 (over 8 weeks) 11.797
inoperable Retroperitoneal
and pelvic
lymph nodes
F 62 Caecum Satellite tumours No No No 65 (over 14 weeks) 17.435
Retroperitoneal
lymph nodes
to assess catheter drainage. The peritoneal cavity was then
left dry until I week prior to initiation of chemotherapy.
The i.p. 5-FU dose of 200 mgm-2 daily was selected to
provide an intermediate dose (compared with previous
studies of intermittent, high-dose 5-FU therapy) which might
be tolerated for the relatively prolonged period of 3 months.
The 5-FU dose of 200 mg m-' daily was aseptically admixed
in 21 of 7.5% icodextrin solution (icodextrin 7.5%, ML
Laboratories) in a twin-bag configuration. prewarmed to
37°C and instilled into the peritoneal cavity by gravity flow
as rapidly as possible (10-20 min). The intraperitoneal drug
delivery system design is shown in Figure 1. Following a 24 h
dwell time, the peritoneal space was drained as completely as
possible in the empty bag of the twin-bag container and
drainage fluid volume was accurately monitored. This proce-
dure was applied from Monday to Friday. Friday's 5-FU i.p.
instillation was only drained on the following Monday after
a 72 h dwell time.
In addition, peritoneal dialysis effluents were examined
cytologically. A total cell count was first performed using an
improved Neubauer counting chamber and a duplicate count
was carried out using a Coulter counter to confirm the
accuracy of these manual counts. Differential cell counts were
performed on cytospin preparations with an optimum cell
dilution to produce an even spread of cells. To obtain a
differential count five standard-sized fields per cytospin were
examined with a minimum of 200 cells counted. The follow-
ing cell types were characterised separately: macrophages.
lymphocytes. neutrophils. eosinophils and mesothelial cells.
Treatment was continued daily for 3 months or until
development of intolerable toxicity or progressive disease.
Drug stabiliti andcompatabilitv
A long-term stability study up to 3 months was conducted on
5-FU from two different sources (Fluoro-Uracil, Roche; and
Fluorouracil injection BP. David Bull Laboratories) aseptic-
ally admixed into two lots of 2 1 glucose polymer solution
(icodextrin 7.5%, ML Laboratories) at the concentrations of
25mgl'. I00mg1-'. 250mgl1' and 500mgl-' at 250C.
Three containers were monitored by combination (drug con-
tent, manufacturer and carrier solution lot) up to 112 days of
storage when protected from light. At weekly intervals, the
admixtures were tested for pH and for 5-FU content by
high-performance liquid chromatography (HPLC) using a
method similar to the HPLC method described by Christo-
phidis et al. (1979) and fully validated for stability assessment.
visual and subvisual particulate matters and osmolality.
Pharmacokinetic studies
Following instillation of an early-morning exchange of 200
mg m- 5-FU in the carrier solution during the first week of
treatment, multiple samples were taken from the peritoneal
dialysate (5 ml aliquots) and from a peripheral vein via an
indwelling catheter (10 ml aliquots into a lithium heparin
tube).
Peritoneal fluid and blood samples were withdrawn con-
currently prior to instillation, at the end of instillation
(10-20 min after the start of instillation) and at 30 min, 1, 2,
4. 8. 12 and 24 h after start of instillation.
C2
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Figur 1 Intraperitoneal drug delivery system. The system con-
tains an intraperitoneal implantable Tenckhoff catheter (A) con-
nected to the integrated twin-bag disconnected system (C) v-ia a
CAPD extension line (B). A drainage container (CI) and a 21
carrer solution container (C2) constitute the integrated twin-bag
system.764 C.S. McARDLE et al.
The blood and peritoneal dialysate samples were kept on
ice, spun at 2.000 r.p.m. for 5 min and the plasma separated
and then frozen at -20'C until analysis. Plasma 5-FU con-
centrations which are below quantitative determination limit
(501g I-') of the HPLC method were measured by a sen-
sitive and specific gas chromatography (GC) - negative ion
chemical ionisation mass spectrometry (NICIMS) method as
previously described (Bates et al.. 1991) and peritoneal
samples by a HPLC method previously used by Goldberg et
al. (1988) and described in detail by Christophidis et al.
(1979).
To achieve long-term steady-state drug concentration in
the plasma and peritoneal compartments. it is necessary to
determine the drug elimination constants (P-phases) in both
compartments in order to establish the rate of continuous
administration of 5-fluorouracil. Therefore, the 5-FU
peritoneal and plasma concentration values were simply fitted
to a first-order linear regression model (In C versus time) in a
linear regression SAS program and goodness of fit was
evaluated by the correlation coefficient. Areas under the
curve (AUC) were calculated from time 0 to 12 h by the
trapezoidal rule.
Results
A total of five patients received 161 exchanges of chemo-
therapy out of the total 235 fluid exchange procedures during
this study: individual treatment duration is listed in Table I.
Out of the five patients. only one patient completed the full
treatment plan of 14 weeks of continuous 5-FU weekdays
exchanges. Another patient received an 8 week treatment of
continuous 5-FU weekdays exchanges. In the three other
patients. IPC treatment was discontinued after 4-5 weeks of
continuous weekday exchanges owing to progressive
disease.
Drug stabilitY andcompatabilitY
Stability of 5-FU when diluted in the glucose polymer carrier
solution was studied over a period of up to 4 months.
The data (listed in Table II) show that the pH of the
admixed solutions ranged from 5.2 to 8.0 depending on 5-FU
Table I1 5-Fluorouracil stabilitv results in icodextrin solutions
5-FL' content
Storage intervals (% ofinitial) Osmolalitia
(das) AMean' s.d.b pHa (.Mosmolkg'j
5-FU at 25 mg I`
O 100.0 0.1 5.25 288
14 97.3 0.1 5.26 289
30 99.7 0.1 5.23 288
70 99.9 0.2 5.22 280
112 101.1 0.2 5.18 289
5-FU at 100mg 11
0 100.0 0.1 5.49 287
14 98.1 0.4 5.51 289
30 100.2 0.1 5.49 286
70 100.5 0.1 5.45 278
112 101.0 0.1 5.44 288
5-FU at 250 mg I'
0 100.0 0.1 7.18 287
14 98.4 0.1 7.15 288
30 100.0 0.1 7.09 287
70 100.3 0.2 6.98 281
112 100.7 0.2 6.94 288
5-FU at 500 mg 1
0 100.0 0.1 7.90 288
14 98.7 0.9 7.86 289
30 99.4 0.2 7.82 289
70 101.6 0.6 7.71 281
112 101.2 0.6 7.60 288
'Mean of three samples. bMean and standard deviation of three
samples analysed in duplicate.
content. Those initial pH values remained unchanged
throughout the test period. The drug concentration of solu-
tions containing 25-500 mg I` 5-FU remained stable for up
to 112 days when stored at 25 ± 3°C protected from light. No
precipitations or increase in subvisible particulate matter
occurred throughout the storage period.
Pharmacokinetic studies
Peritoneal and plasma concentration versus time (semi-
logarithmic) curves on the five tested patients are shown in
Figure 2. The i.p. 5-FU concentrations are approximately
1,000-fold higher than plasma concentrations. After a
relatively short lag time, drug appears in the plasma com-
partment. where a maximum peak level is achieved within
30 min post i.p. instillation. After this quick absorption
distribution phase (a-phase). the elimination phase (a-phase)
also follows a first-order model, and 5-FU was still detectable
in both fluids 12 h post instillation. This apparent first-order
5-FU clearance in both compartments can be expressed by
the following equations:
wn Chi pe(t) = cnCentatonn -kLpet
where C,p is the drug concentration in pentoneal fluid or
In Cql(t) = In Cp,(0)-kpjt
where Cp, is the drug concentration in plasma. Pen'toneal
clearance (PA) can be expressed as PA = k x V.p. If the
a-phase half-life (a-phase t,) in both compartments is ex-
pressed by tj = 0.693 k, then the frphase 5-FU apparent
elimination constants (ki,p and kp,) can be deduced.
Peritoneal clearance obtained from this equation was
found to be 15.8 ± 5.6 ml min '. whereas a value of
15.6 ± 5.2 ml min-' was found when calculated as the con-
ventional doselperitoneal AUC ratio. a-phase half-life values
are respectively 1.28 ± 0.21 and 1.28 ± 0.15 for peritoneal
and plasma compartments, and 5-FU apparent elimination
constants are similar in both compartments (0.51 ± 0.02 and
0.56 ± 0.04 in peritoneum and plasma respectively).
Total body clearances (expressed as total absorbed dose
plasma AUC ratio) varied between 5 and 261 min-' (Table
III).
Peritonealfluid balanceprofile
Dunrng the whole study a total of 344.55 1 (or kg) of carrier
solution was instilled (ranging from 29.75 to 125.00 1 per
patients) and 344.91 1 (or kg) was drained (ranging from
15.95 to 138.36 1 per patient). For the two patients undergo-
ing long-term i.p. dialysis (Figure 3) the volume balance
percentages after 24 h exchanges were mostly stable with time
and ranged from 0 to -50% (which means that for 2 1 of
carrier solution with 5-FU instilled 2-3 1 were drained 24 h
later). This was not associated with electrolyte disturbance or
dehydration.
1000.0000
- 100.0000
E 10.0000
c
0
as 1.0000
CD L-
CD 0.1000 u
) 0.0100
L) 0.0010
0.00011
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (h)
Figwe 2 5-Fluorouracil peritoneal ( ) and plasma (- - -)
levels achieved post i.p. installation of 200 mgm~- 5-fluorouracil
in the carrier solution in five patients (*, A. *. *. *).
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Figure 3 Volume balance percentage levels post 24 h exchange in
two patients (M. *) undergoing long-term i.p. chemotherapy.
Volume balance percentage is expressed as the relative difference
level between inflow and outflow volumes: [(inflow - outflow)
inflow] x 100.
C}ytology
For each weekday specimen, the total white cell count and
the percentages of mesothelial cells, neutrophil polymorphs,
macrophages, eosinophils and lymphocytes were monitored.
The percentages of mesothelial cells, macrophages, eosino-
phils and lymphocytes did not differ significantly from those
observed in patients starting CAPD (Fok et al., 1989).
On the weekdays, total cell counts and the percentage of
neutrophil polymorphs regularly exceeded the criteria for
peritonitis (2 x 108cells I` and ) 50% polymorphs) in the
absence of clinical and bacteriological evidence ofperitonitis.
Therefore, classical leucocytes and polymorph levels as diag-
nostic limits for peritonitis in CAPD (Antonsen et al., 1991)
are not relevant in these patients. Furthermore, cell counts
are apparently unaffected by chemotherapy.
Toxicitr and complications
Continuous weekdays i.p. exchanges of 5-FU 200 mg m'
day-' lasting i.p. to 3 months in one patient and for a
shorter time for the other patients resulted in no treatment-
associated toxicity worse than WHO grade 2. Those WHO
grade 2 toxicity incidences included nausea and vomiting and
diarrhoea occurring in two patients after 6 weeks of therapy
and was treated successfully with antiemetics and loperamide
as an antidiarrhoeal agent. During the whole 235 fluid
exchanges or 470 connections and disconnections, no
bacterial peritonitis or exit site infection events were
observed.
The study clearly demonstrates the feasibility of long-term
continuous weekdays administration of 5-FU i.p. chemo-
therapy for up to 3 months on an ambulatory treatment
basis. This report once again demonstrates the pharmaco-
logical advantage that can be achieved by i.p. instillation of
chemotherapy. 5-FU concentration ratios between the peri-
toneal fluid and plasma were about 1,000 for all patients.
Interestingly, the peritoneal and plasma 5-FU concentration
versus time semilogarithmic curves are parallel for up to 12 h
post i.p. instillation, leading to an apparent plasma 5-FU
half-life similar to the i.p. 5-FU half-life of around 1.3 h,
which is significantly longer than plasma 5-FU half-life of
0.2 h when 5-FU was administered by the i.v. route (Goldberg
et al., 1988). Furthermore, the novel camrer solution did not
affect the 5-FU pharmacokinetic paraneters compared with
previous studies with other carrier solutions (1.5% dextrose
dialysate or lactated Ringer's solution) (Speyer et al., 1980,
1981; Demicheli et al., 1982; Arbuck et al., 1986; Campora et
al., 1987; Schilsky et al., 1990; Sugarbaker et al., 1990).
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The relatively constant peritoneal fluid balance achieved
with this new carrier solution ensures maximal coverage of
peritoneal areas liable to bear tumours for 24 h. This allows
a single daily exchange, which is a much more viable pro-
spect for prolonged out-patient dialysis than some of the
schedules previously used (for example eight 4-hourly
exchanges repeated monthly) (Speyer et al.. 1980. 1981;
Arbuck et al.. 1986). The constant peritoneal fluid balance
achieved with the carrier solution combined with the 'state of
the art peritoneal twin-bag delivery system gives long-term
and feasible access to the peritoneal cavity with no incidence
of exit site infection and bacterial peritonitis in this feasibility
study.
Based on the pharmacokinetic parameters from the present
study we have designed a loading dose infusion schedule in
an attempt to maintain steady-state i.p. 5-FU levels.
We have initiated a multicentre phase I study in collabora-
tion with ML Laboratories to determine the maximum toler-
able dose (MTD) values for continuous long-term i.p. treat-
ment for 3 months in patients with advanced colorectal.
gastnc and ovanran cancer.
The authors gratefully acknowledge the expert support of Dr F.
Mutch for the cytological studies. thank R. Blackie for his expert
technical assistance in 5-fluorouracil analysis in biological fluids. and
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Campaign. UK.
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